Reimbursed Care Access in Guadeloupe

Currently classified as a strictly controlled substance under the French lists of narcotics; there is no authorised medical use outside approved clinical research in France (and therefore in Guadeloupe). The national decree fixing the list of substances classified as stupéfiants explicitly lists "Psilocybine" and related mushroom preparations. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA ("MDMA ou dl N, -diméthyl (méthylènedioxy)-3,4 phényléthylamine") is listed in the French arrêté of 22 February 1990. #

Esketamine (SPRAVATO®) has a European marketing authorisation and is available in France under hospital‑use conditions for treatment‑resistant depressive episodes in adults (used in association with an oral antidepressant) and has a defined reimbursement position from the French Haute Autorité de Santé (HAS). The HAS has published an opinion supporting maintenance of reimbursement under restricted conditions (e.g., adults under 65, severe treatment‑resistant depression after failure of at least two oral antidepressants during the current episode). Prescription is hospital‑only, limited to psychiatric specialists, delivered under monitored conditions (secure prescription, observation after administration). #

Because Guadeloupe is a French department, these national regulatory and reimbursement arrangements apply on the territory; SPRAVATO® is provided via hospital channels and reimbursement/coverage follows the national rules and hospital procurement processes. For background on hospital availability and the initial derogatory hospital arrangements in France prior to wider availability, see contemporaneous French communications summarising hospital rollout and ATU arrangements. #

Ketamine (the racemic mixture and its salts) is controlled under the French narcotics lists but remains a licensed medicinal product for anaesthesia and other authorised indications; additionally, low‑dose/infusion use of ketamine for treatment‑resistant depression is performed in specialised centres in France as an off‑label intervention. The arrêté listing the controlled substances explicitly names "Kétamine et ses sels, à l'exception de leurs préparations injectables" (meaning ketamine is controlled while recognised injectable preparations remain a regulated medicinal use). #

Clinical context and access: off‑label IV ketamine infusions for depression are delivered in private or hospital specialist settings (psychiatric centres, private clinics). These interventions are generally billed directly to the patient or via private health insurance; routine, systematic reimbursement by the French national health insurance for IV ketamine as an antidepressant is not established in the way that SPRAVATO® has a specific hospital pathway and HAS reimbursement decision. Guidance, centre descriptions and press/medical reviews document specialised clinics offering paid ketamine infusion protocols in France. #

Regional application: because Guadeloupe is an integral French department, the same legal classification and the same reimbursement framework apply; however, local availability of specialised IV ketamine services is likely limited (most specialised centres are in metropolitan France) and patients in Guadeloupe seeking off‑label ketamine infusion commonly travel to metropolitan centres or private clinics that publish fee schedules. (See private clinic service pages for example pricing and service models.)

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. DMT ("DMT ou N,N-diméthyltryptamine") is explicitly listed in the French arrêté. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While 5‑MeO‑DMT is not separately named in every listing iteration, French narcotics law and analog provisions have been used to control similar tryptamine derivatives, and preparations such as hallucinogenic natural teas and extracted DMT/harmala components have been explicitly listed or controlled historically; possession/use therefore has no authorised medical pathway outside formal approved trials. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine and Tabernanthe iboga products are explicitly listed in the French arrêté and France treats ibogaine as a controlled narcotic (historical notes confirm formal listing and Conseil d'État confirmations). #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The plants and active β‑carbolines/harmala constituents and common DMT‑containing species that compose ayahuasca have been specifically mentioned in French regulatory texts and court rulings that resulted in the common ingredients being declared stupéfiants; consequently ayahuasca preparations are not authorised for medical use outside approved trials. Historical French court decisions (Santo Daime) and subsequent regulatory listings have made the components illegal. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline is explicitly listed in the French arrêté of 22 February 1990. Note that botanical exceptions (e.g., peyote plant regulatory treatments) do not create general authorised medical access in France; mescaline itself remains controlled. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2‑C family substances (e.g., 2‑CI, 2‑CB and other related substituted phenethylamines) are named in the French controlled substances lists; novel 2C derivatives are controlled by name or analogue provisions. #